12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bronchitol mannitol regulatory update

Pharmaxis said Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recommended against including cystic fibrosis drug Bronchitol mannitol for reimbursement on the Australian Pharmaceutical Benefits Scheme (PBS). According to Pharmaxis, PBAC said the decision is due to "uncertainties in where Bronchitol will...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >